What You Should Know:
– Evidation Health raises $45M in Series D funding to expand its privacy-first, direct-to-person research platform to the virtual health market.
– Evidation Health will use this new investment to enable Achievers to gain clinically actionable insights into their health. The first of these new virtual health offerings is slated for release later this year.
– To help guide the company as it ushers in this new era, Evidation has also hired Sam Marwaha as Chief Commercial Officer.
Evidation Health, a San Mateo, CA-based digital health company announced it has raised $45 million in Series D funding to expand its privacy-first, direct-to-person research platform, Achievement to the virtual health market. The Series D round was led by B Capital Group with participation from new investors McKesson Ventures and Section 32 as well as existing investors Revelation Partners, Rethink Impact, and SV Health Investors. B Capital’s Adam Seabrook has joined Evidation’s Board of Directors. Sam Marwaha, Senior Partner at Boston Consulting Group.
Founded in 2012 by GE Ventures and Stanford Health Care, Evidation measures health in everyday life and enables anyone to participate in ground-breaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation’s Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster.
Chief Commercial Officer Appointment
To help guide the company as it ushers in this new era, Evidation has also hired Sam Marwaha as Chief Commercial Officer. Marwaha is a 20-year veteran of the industry who will scale Evidation’s marketing and business development teams, and he will also shape new opportunities to help people achieve better outcomes through virtual health.
“Evidation is a learning engine directly connected to four million people, making it possible to understand real-life indicators of health quality and disease progression, reflecting behavioral and social factors,” said Marwaha. “Evidation can drive personalized, consented engagement with individuals in the safety and convenience of their homes, empowering them to be partners in their own health.”
Achievement Platform Expansion
Evidation will use this new capital to build upon its existing evidence generation capabilities to offer real-time insights and digital tools to its network of nearly 4 million individuals. The company will leverage this investment to continue to rapidly grow its study solutions business and offer programs that enable Achievement members to gain clinically actionable insights into their health. This includes connecting relevant digital interventions, treatments, and tools to help individuals understand and take advantage of the latest evidence, in partnership with their care teams.
Expansion to Virtual Health
The first of these new virtual health offerings is slated for release later this year. Evidation also will continue to expand and diversify the Achievement population — already the largest and most demographically and geographically diverse connected cohort in the United States — to serve additional at-risk and disease-specific cohorts. Achievement already includes participants residing in all 50 states and in 9 out of every 10 ZIP codes nationwide.
“Participation in research is an activator for individuals to better understand their health and seek care proactively,” said Evidation CEO Deborah Kilpatrick, Ph.D. “The natural next step for Evidation is to decrease the latency between evidence and action by offering virtual health programs, while still keeping privacy and consent at the forefront. We are especially excited to have Sam Marwaha, a pioneer in real-world evidence and an experienced digital health strategist and operator, join us to lead our commercial endeavors as the company ushers in a new era of self-activated care.”
This funding and C-suite hire caps off a fast-paced growth period for Evidation. Eight of the top 10 global biopharma companies rely on Evidation for person-generated health data (PGHD), including passive sensor data, electronic patient-reported outcomes (ePROs), and at-home diagnostics. Johnson & Johnson, Apple, and Evidation recently launched the ongoing Heartline Study, the largest randomized trial in the history of cardiovascular disease. Evidation is also working with a diverse cross-section of partners in industry, academia, government, and civil society, including the Icahn School of Medicine at Mount Sinai, the Biomedical Advanced Research and Development Authority (BARDA), and the Bill & Melinda Gates Foundation, on efforts to better detect, characterize and predict COVID-19 using PGHD.
“COVID-19 has shown us that accelerating real world evidence development is critical,” said Mike Pellini, MD, Managing Partner of Section 32 and former CEO and Chairman of Foundation Medicine. “Evidation has led the way in health measurement and has proven out the potential of person-generated health data. The company is optimally positioned to lead the way into a new era of individualized healthcare.”